The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation

被引:80
作者
Follo, Matilde Y.
Mongiorgi, Sara
Bosi, Costanza
Cappenini, Alessandra
Finelli, Carlo
Chiarini, Francesca
Papa, Veronica
Libra, Massimo
Martinelli, Giovanni
Cocco, Lucio
Martelli, Alberto M.
机构
[1] Univ Bologna, Dipartimento Sci Anat Umane & Fisiopatol Apparato, Cell Signaling Lab, Sez Anat, I-40126 Bologna, Italy
[2] Univ Bologna, Ist Ematol & Oncol Med L EA Seragnoli, I-40126 Bologna, Italy
[3] CNR, Ist Genet Mol, IOR, I-40126 Bologna, Italy
[4] Univ Cassino, Sez Anat, Dipartimento Sci Motorie & Salute, I-03043 Cassino, Italy
[5] Univ Catania, Dipartimento Sci Biomed, Catania, Italy
关键词
D O I
10.1158/0008-5472.CAN-06-4409
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The Akt/mammalian target of rapamycin (mTOR) signaling pathway is important for both cell growth and survival. In particular, an impaired regulation of the Akt/mTOR axis has been strongly implicated in mechanisms related to neoplastic transformation, through enhancement of cell proliferation and survival. Myelodysplastic syndromes (MDS) are a group of heterogeneous hematopoietic stem cell disorders characterized by ineffective hematopoiesis and by a high risk of evolution into acute myelogenous leukemia (AML). The pathogenesis of the MDS evolution into AML is still unclear, although some recent studies indicate that aberrant activation of survival signaling pathways could be involved. In this investigation, done by means of immunofluorescent staining, we report an activation of the Akt/mTOR pathway in high-risk MDS patients. Interestingly, not only mTOR was activated but also its downstream targets, 4E-binding protein 1 and p70 ribosomal S6 kinase. Treatment with the selective mTOR inhibitor, rapamycin, significantly increased apoptotic cell death of CD33(+) (but not CD33(-)) cells from high-risk MDS patients. Rapamycin was ineffective in cells from healthy donors or low-risk MDS. Moreover, incubation of high-risk MDS patient CD34(+) cells with rapamycin decreased the in vitro clonogenic capability of these cells. In contrast, the phosphoinositide 3-kinase inhibitor, LY294002, did not significantly affect the clonogenic activity of high-risk MDS cells. Taken together, our results indicate that the Akt/mTOR pathway is critical for cell survival and proliferation in high-risk MDS patients. Therefore, this signaling network could become an interesting therapeutic target for treating more advanced MDS cases.
引用
收藏
页码:4287 / 4294
页数:8
相关论文
共 51 条
[1]   Regulation of Akt/PKB by phosphatidylinositol 3-kinase-dependent and -independent pathways in B-cell chronic lymphocytic leukemia cells:: role of protein kinase Cβ [J].
Barragan, Montserrat ;
de Frias, Merce ;
Iglesias-Serret, Daniel ;
Campas, Clara ;
Castano, Esther ;
Santidrian, Antonio F. ;
Coll-Mulet, Llorenc ;
Cosialls, Ana M. ;
Domingo, Alicia ;
Pons, Gabriel ;
Gil, Joan .
JOURNAL OF LEUKOCYTE BIOLOGY, 2006, 80 (06) :1473-1479
[2]   Activation of AKT kinases in cancer: Implications for therapeutic targeting [J].
Bellacosa, A ;
Kumar, CC ;
Di Cristofano, A ;
Testa, JR .
ADVANCES IN CANCER RESEARCH, VOL 94, 2005, 94 :29-+
[3]   PROPOSALS FOR THE CLASSIFICATION OF THE MYELODYSPLASTIC SYNDROMES [J].
BENNETT, JM ;
CATOVSKY, D ;
DANIEL, MT ;
FLANDRIN, G ;
GALTON, DAG ;
GRALNICK, HR ;
SULTAN, C .
BRITISH JOURNAL OF HAEMATOLOGY, 1982, 51 (02) :189-199
[4]   A selective inhibitor of the p110δ isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16 [J].
Billottet, C. ;
Grandage, V. L. ;
Gale, R. E. ;
Quattropani, A. ;
Rommel, C. ;
Vanhaesebroeck, B. ;
Khwaja, A. .
ONCOGENE, 2006, 25 (50) :6648-6659
[5]   Assessment of somatic mutations in phosphatidylinositol 3-kinase gene in human lymphoma and acute leukaemia [J].
Bousquet, M ;
Recher, C ;
Quelen, C ;
Demur, C ;
Payrastre, B ;
Brousset, P .
BRITISH JOURNAL OF HAEMATOLOGY, 2005, 131 (03) :411-413
[6]   Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myelold transformation [J].
Brandts, CH ;
Sargin, B ;
Rode, M ;
Biermann, C ;
Lindtner, B ;
Schwäble, J ;
Buerger, H ;
Müller-Tidow, C ;
Choudhary, C ;
McMahon, M ;
Berdel, WE ;
Serve, H .
CANCER RESEARCH, 2005, 65 (21) :9643-9650
[7]  
Braun T, 2006, BLOOD, V107, P1156
[8]   Myelodysplasic syndromes: A comprehensive review [J].
Catenacci, DVT ;
Schiller, GJ .
BLOOD REVIEWS, 2005, 19 (06) :301-319
[9]   Nuclear phospholipase C β1, regulation of the cell cycle and progression of acute myeloid leukemia [J].
Cocco, L ;
Manzoli, L ;
Palka, G ;
Martelli, AM .
ADVANCES IN ENZYME REGULATION, VOL 45, 2005, 45 :126-135
[10]   The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism [J].
Engelman, Jeffrey A. ;
Luo, Ji ;
Cantley, Lewis C. .
NATURE REVIEWS GENETICS, 2006, 7 (08) :606-619